Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Mari Mino-Kenudson, M.D.

Co-Author

This page shows the publications co-authored by Mari Mino-Kenudson and Justin Gainor.
Connection Strength

2.818
  1. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016 Sep 15; 22(18):4585-93.
    View in: PubMed
    Score: 0.681
  2. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol. 2020 12; 31(12):1725-1733.
    View in: PubMed
    Score: 0.230
  3. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol. 2020 03; 31(3):404-411.
    View in: PubMed
    Score: 0.218
  4. Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. Mod Pathol. 2019 04; 32(4):511-523.
    View in: PubMed
    Score: 0.201
  5. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2017; 2017.
    View in: PubMed
    Score: 0.185
  6. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. J Thorac Oncol. 2017 03; 12(3):458-466.
    View in: PubMed
    Score: 0.176
  7. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. J Thorac Oncol. 2016 11; 11(11):1869-1878.
    View in: PubMed
    Score: 0.173
  8. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
    View in: PubMed
    Score: 0.172
  9. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4273-81.
    View in: PubMed
    Score: 0.139
  10. Characteristics and Outcomes of Lung Cancers Detected on Low-Dose Lung Cancer Screening CT. Cancer Epidemiol Biomarkers Prev. 2021 Aug; 30(8):1472-1479.
    View in: PubMed
    Score: 0.060
  11. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis Oncol. 2020; 4:21.
    View in: PubMed
    Score: 0.057
  12. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
    View in: PubMed
    Score: 0.050
  13. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):135-140.
    View in: PubMed
    Score: 0.050
  14. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.049
  15. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018 07; 8(7):822-835.
    View in: PubMed
    Score: 0.049
  16. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729.
    View in: PubMed
    Score: 0.049
  17. Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220.
    View in: PubMed
    Score: 0.045
  18. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 05; 12(5):872-877.
    View in: PubMed
    Score: 0.044
  19. MET Exon 14 Skipping in Non-Small Cell Lung Cancer. Oncologist. 2016 Apr; 21(4):481-6.
    View in: PubMed
    Score: 0.042
  20. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2016 Jan; 3:54-66.
    View in: PubMed
    Score: 0.041
  21. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014 Dec 19; 346(6216):1480-6.
    View in: PubMed
    Score: 0.038
  22. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013 Jun 20; 368(25):2395-401.
    View in: PubMed
    Score: 0.035
  23. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.